Big Pharma's Cardiovascular Comeback Is Reshaping Who Gets Deals Done

The Buyers Are Back

Cardiovascular used to be where pharma went to print money. Then it became where pharma went to cut costs. Lipitor went generic, PCSK9 inhibitors underwhelmed on launch, and the entire therapeutic area got tagged as commercially exhausted. BD teams pivoted to oncology. Cardiovascular assets languished.

That era is over. Across the transactions we track, cardiovascular deal activity has picked up materially over the past eighteen months, driven by a convergence that was years in the making: the clinical validation of new mechanism classes, the commercial proof-of-concept from Novo Nordisk's cardiometabolic franchise, and the looming reality that several large-cap pharma companies face cardiovascular-shaped holes in their 2028-2032 revenue projections.

What's different this time is the buyer composition. This isn't a single acquirer overpaying to fill a gap. Multiple large pharma counterparties are actively sourcing cardiovascular assets simultaneously — and they're competing with each other in ways they haven't since the statin wars of the early 2000s.

Who's Writing Checks and Why

The most instructive recent transaction remains AstraZeneca's $1 billion-plus acquisition of CinCor Pharma in 2023, which signaled that large pharma was willing to pay meaningful premiums for differentiated cardiorenal mechanisms. That deal wasn't an anomaly — it was a leading indicator. Since then, we've seen Bristol Myers Squibb acquire Milvexian rights through its RayzeBio and Karuna plays while doubling down on its Factor XIa program, Novartis continue to build around its post-Entresto cardiovascular franchise, and Johnson & Johnson position its cardiovascular surgery and interventional portfolio for the next cycle.

The underlying driver is straightforward: GLP-1 receptor agonists have reframed cardiovascular risk reduction as a massive, undertreated commercial opportunity. Novo Nordisk's SELECT trial didn't just validate semaglutide for cardiovascular outcomes — it reminded every pharma CEO that cardiovascular disease is still the world's leading killer, and that the addressable market dwarfs what their oncology pipelines can deliver.

Now the question for BD executives isn't whether to source cardiovascular assets. It's which mechanism classes to prioritize and what to pay.

The Mechanism Classes Drawing Competition

Three broad mechanism areas are generating the most counterparty interest in our dataset:

Cardiometabolic crossover assets. Anything adjacent to the GLP-1/obesity/cardiovascular intersection is seeing aggressive inbound interest. This includes dual and triple incretin agonists, GIPR modulators, and amylin analogs with cardiovascular endpoint data or credible paths to MACE-driven outcomes trials. The challenge: these assets are expensive, and the competitive dynamics with Novo Nordisk and Eli Lilly create valuation compression risk for acquirers who arrive late.

Novel anticoagulation and antithrombotic mechanisms. Factor XIa inhibitors represent the most advanced class here, with multiple programs in Phase 2 and Phase 3. The thesis is simple — separate the antithrombotic benefit from the bleeding risk that has plagued warfarin and DOACs for decades. BMS, Bayer, and several mid-cap specialty pharma companies are all active in this space, either through internal programs or external sourcing.

Heart failure beyond neurohormonal modulation. Entresto proved you could build a $5 billion-plus franchise in heart failure. Now buyers are looking at cardiac myosin activators, soluble guanylate cyclase stimulators, and gene therapy approaches targeting specific cardiomyopathy subtypes. These tend to be earlier-stage, higher-risk, but the structural economics are attractive — smaller patient populations with clear endpoints and favorable regulatory paths.

What's notably absent from active sourcing is traditional lipid-lowering. The PCSK9 space has consolidated, and the remaining opportunity in LDL-C reduction feels incremental. Buyers are looking for mechanisms that address residual cardiovascular risk beyond LDL.

Deal Structures Are Skewing Toward Control

The structural patterns emerging in cardiovascular transactions diverge from what we see in other therapeutic areas. In oncology, for example, option-based collaborations and co-development structures remain common. In cardiovascular, buyers are pushing harder for outright acquisitions or exclusive worldwide licenses with control provisions that look a lot like acquisitions.

The logic is timing. Cardiovascular outcomes trials are long — three to five years in many cases — and buyers want to control the clinical development strategy without negotiating milestone-by-milestone with a licensor. That means upfront payments tend to be larger relative to total deal value than in therapeutic areas with shorter development timelines, because the buyer is essentially prepaying for the right to run a five-year trial without interference.

For founders, this has a concrete implication: cardiovascular deals tend to close with higher upfront-to-total-value ratios but lower headline numbers than comparable oncology transactions. A cardiovascular licensing deal with $150 million upfront and $800 million in milestones is structurally aggressive by historical standards for the therapeutic area, even if it looks modest next to a billion-dollar oncology option deal with $50 million upfront.

The milestone structures themselves skew heavily toward clinical and regulatory events rather than commercial targets. Buyers want to pay for data readouts and approvals, not sales thresholds — because they believe they can handle commercialization themselves in a therapeutic area where they already have established field forces and KOL relationships.

These benchmarks are available in real-time on Solidus, our deal terms platform.

Implications

If you're a cardiovascular-focused biotech preparing for a deal process, the current environment is the most favorable in at least a decade. Multiple large pharma counterparties are actively sourcing, which creates competitive tension you can use. But you need to understand what they're buying: mechanism differentiation, not just clinical-stage assets. If your program is a me-too in a crowded class, the buyer pool shrinks fast. If you have a differentiated mechanism with a credible path to cardiovascular outcomes data, you're in a seller's market. Structure your process accordingly — run it formally, engage multiple counterparties, and don't accept the first term sheet.

On valuation, calibrate expectations to the therapeutic area, not to oncology comps. Cardiovascular deals have historically traded at lower multiples to peak sales than oncology transactions, partly because of longer development timelines and partly because of reimbursement dynamics. That gap is narrowing — the GLP-1 cardiovascular data has shown payers that cardiovascular outcomes matter commercially — but it hasn't closed. A reasonable expectation for a Phase 2 cardiovascular asset with differentiated mechanism data is an upfront payment in the range of what comparable Phase 2 oncology assets commanded two to three years ago. The market is catching up, not caught up.

For pharma BD teams, the window for acquiring cardiovascular assets at pre-competition pricing is closing. The number of active buyers in this space has increased faster than the supply of quality assets. If your cardiovascular strategy depends on external innovation — and for most large pharma companies outside of Novartis, it does — the time to execute is now. Waiting for Phase 3 readouts to de-risk your thesis will price you out of the best assets. The counterparties willing to underwrite Phase 2 risk in cardiovascular today will own the therapeutic area's next franchise. The ones waiting for pivotal data will be negotiating from a position of weakness, competing against established owners who already control the most differentiated programs.